Anti-Human BST2 Therapeutic Antibody (XmAb 5592)

Cat. No.: TAB-075CL
This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview
Recombinant Humanized monoclonal antibody expressed in CHO binding to Human BST2. XmAb5592, a humanized anti-HM1.24 mAb with Fc-domain engineered to significantly enhance FcγR binding and associated immune effector functions. The clinical development of XmAb5592, both as a monotherapy and in combination with lenalidomide, to improve patient outcome of multiple myeloma (MM).

Target
BST2

Derivation
Humanized

Species Reactivity
Human

Type
Antibody

Expression Host
CHO

Purity
90–95% (SDS-PAGE)

Applications
Cyt, Inhib, FuncS

Application Notes
The antibody was validated for Cytotoxicity, Inhibition, Function Assay. For details, refer to Published Data.

Storage
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Related Disease
Multiple Myeloma

BACKGROUND
**Introduction**

XmAb5592, a humanized anti-HM1. 24 mAb with Fc-domain engineered to significantly enhance FcγR binding and associated immune effector functions. The clinical development of XmAb5592, both as a monotherapy and in combination with lenalidomide, to improve patient outcome of multiple myeloma (MM).

**Alternative Names**

BST2; bone marrow stromal cell antigen 2; CD317; TETHERI

**Gene ID**

684

**UniProt ID**

Q10589